

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

1-2. (Canceled)

3. (Previously presented) An isolated antibody comprising a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 143, 144 and 158, respectively.

4-5. (Canceled)

6. (Previously presented) An isolated antibody selected from the group consisting of the antibody of any one of (1) - (7):

(1) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 84 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92;

(2) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 85 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92;

(3) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 86 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92;

(4) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 87 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92;

(5) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 88 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92;

(6) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 89 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92; and

(7) an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 90 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 92.

7. (Previously presented) The antibody as claimed in claim 3 or 6, which is a humanized antibody.

8-13. (Canceled)

14. (Currently amended) An isolated monoclonal antibody capable of binding to a peptide consisting of the sequence of the amino acid residues 546 - 551 of glypican 3.

15. (Previously presented) The antibody as claimed in claim 14 or 16, which is a humanized antibody.

16. (Currently amended) An isolated monoclonal antibody capable of binding to an epitope to which a second antibody is capable of binding, wherein said second antibody comprises a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 143, 144 and 158, respectively.

17-18. (Canceled)

19. (Withdrawn) A polynucleotide coding for a heavy chain variable region or a light chain variable region of the antibody as claimed in claim 7 or 8.

20. (Withdrawn) The polynucleotide as claimed in Claim 19 having the sequence set forth in any one of SEQ ID NOs: 11-21, 33-43, 55-59, 65-70 and 77-83.

21. (Previously presented) A pharmaceutical composition comprising the antibody as claimed in claim 3.

22. (Previously presented) A pharmaceutical composition comprising the antibody as claimed in claim 6.

23. (Canceled)

24. (Withdrawn) A peptide comprising the amino acid sequence of the amino acid residues 524 - 563 of glypican 3.

25. (Withdrawn) A peptide comprising the amino acid sequence of the amino acid residues 537 - 563 of glypican 3.

26. (Withdrawn) A peptide comprising the amino acid sequence of the amino acid residues 544 - 553 of glypican 3.

27. (Withdrawn) A peptide comprising the amino acid sequence of the amino acid residues 546 - 551 of glypican 3.

28. (Canceled)

29. (Previously presented) An isolated antibody comprising any one of (1) - (15) below:

(1) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 174, 144 and 158, respectively;

(2) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 175, 144 and 158, respectively;

(3) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 176, 144 and 158, respectively;

(4) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 177, 144 and 158, respectively;

(5) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 178, 144 and 158, respectively;

(6) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 179, 144 and 158, respectively;

(7) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 180, 144 and 158, respectively;

(8) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 181, 144 and 158, respectively;

(9) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 182, 144 and 158, respectively;

(10) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 183, 144 and 158, respectively;

(11) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 184, 144 and 158, respectively;

(12) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124, and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 185, 144, and 158, respectively;

(13) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124, and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 186, 144 and 158, respectively;

(14) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 187, 144 and 158, respectively; and

(15) a heavy chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 123, 124 and 125, respectively, and a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO: 188, 144 and 158, respectively.

30-31. (Canceled)

32. (Currently amended) The antibody as claimed in any one of claims 14, 16, and 29, which is a human antibody.

33. (Canceled)

34. (Previously presented) The antibody as claimed in claim 14, which binds to a peptide separated by SDS-PAGE under reducing conditions as analyzed by Western blotting.

35. (Canceled)

36. (Previously presented) A pharmaceutical composition comprising the antibody as claimed in claim 14.

37. (Previously presented) A pharmaceutical composition comprising the antibody as claimed in claim 15.

38. (Previously presented) A pharmaceutical composition comprising the antibody as claimed in claim 16.

39. (Previously presented) A pharmaceutical composition comprising the antibody as claimed in claim 29.

40. (Canceled)

41. (Previously presented) A pharmaceutical composition comprising the antibody as claimed in claim 32.

42. (Canceled)

43. (Withdrawn - currently amended) A method for inhibiting cell growth comprising administering to a subject the antibody as claimed in any one of claims 3, 6, [[8,]] 14, 16, and 29, ~~31, and 35~~.

44. (Withdrawn - currently amended) A method for treating hepatoma comprising administering to a subject the antibody as claimed in any one of claims 3, 6, [[8,]] 14, 16, and 29, ~~31, and 35~~.

45. (Withdrawn - currently amended) A method comprising contacting a hepatoma cell with the antibody as claimed in any one of claims 3, 6, [[8,]] 14, 16, and 29, ~~31, and 35~~.

46. (Withdrawn) The method of claim 45, wherein the contacting occurs in vivo.

47. (New) A pharmaceutical composition comprising the antibody as claimed in claim 7.

48. (New) A method for inhibiting cell growth comprising administering to a subject the antibody as claimed in claim 7.

49. (New) A method for treating hepatoma comprising administering to a subject the antibody as claimed in claim 7.

50. (New) A method comprising contacting a hepatoma cell with the antibody as claimed in claim 7.

51. (New) A method for inhibiting cell growth comprising administering to a subject the antibody as claimed in claim 15.

52. (New) A method for treating hepatoma comprising administering to a subject the antibody as claimed in claim 15.

53. (New) A method comprising contacting a hepatoma cell with the antibody as claimed in claim 15.